In Reply In response to our study on tapering of csDMARDs in patients with RA in remission,1 Dr Baker and colleagues discuss the potential for successful tapering, and even drug-free remission, in RA. They highlight that our study results can be interpreted differently than the main conclusion of the article, which was also discussed in the Editorial by Curtis et al.2
Lillegraven S, Paulshus Sundlisæter N, Haavardsholm EA. Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients With Rheumatoid Arthritis—Reply. JAMA. 2021;326(9):873. doi:10.1001/jama.2021.10651
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.